FMP

FMP

Enter

NNVC - NanoViricides, ...

photo-url-https://images.financialmodelingprep.com/symbol/NNVC.png

NanoViricides, Inc.

NNVC

AMEX

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

1.36 USD

-0.02 (-1.47%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. Anil R. Diwan Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

AMEX

Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the externa...

CIK

0001379006

ISIN

US6300873022

CUSIP

630087302

Address

1 Controls Drive

Phone

203 937 6137

Country

US

Employee

7

IPO Date

Oct 26, 2005

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

NNVC Financial Summary

CIK

0001379006

Exchange

AMEX

Industry

Biotechnology

Sector

Healthcare

CUSIP

630087302

ISIN

US6300873022

Country

US

Price

1.36

Beta

0.97

Volume Avg.

152.2k

Market Cap

19.51M

Shares

-

52-Week

1.0-3.59

DCF

0.4

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.79

P/B

-

Website

https://www.nanoviricides.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest NNVC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep